FORUM Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2001-01-01
- Employees
- 51
- Market Cap
- -
Clinical Trials
46
Active:24
Completed:16
Trial Phases
3 Phases
Phase 1:22
Phase 2:6
Phase 3:8
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (36 trials with phase data)• Click on a phase to view related trials
Phase 1
22 (61.1%)Phase 3
8 (22.2%)Phase 2
6 (16.7%)Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine
- First Posted Date
- 2014-09-22
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Registration Number
- NCT02246075
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 30
- Registration Number
- NCT02149160
- Locations
- 🇺🇸
UCSF Memory and Aging Center, San Francisco, California, United States
🇺🇸Compass Research, LLC, Orlando, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics
Phase 1
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2015-01-12
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 40
- Registration Number
- NCT02037074
Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 348
- Registration Number
- NCT02004392
Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 14
- Registration Number
- NCT02001389
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found